TAVO101
TAVO101 is a humanized anti-TSLP antibody with an EC50 of 0.19 nM against hTSLP. TAVO101 inhibits STAT5 activation and CCL17 release. TAVO101 carries Fc region mutations that enhance its binding to FcRn while reducing its binding to FcγRI, FcγRIIIA and C1q, thereby attenuating effector functions. TAVO101 reduces the levels of inflammatory markers, cell infiltration and histopathological damage in preclinical models of asthma, psoriasis and atopic dermatitis. TAVO101 can be used for research related to asthma, psoriasis and atopic dermatitis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human
|
STAT5 |
TAVO101 (Serial 3-fold dilutions starting at 1 μg/mL; 2 hours at room temperature) potently binds human TSLP with an EC50 of 29.06 ng/mL (0.19 nM) and exhibits no cross-reactivity to cynomolgus monkey or mouse TSLP[1].
TAVO101 (Serial 3-fold dilutions starting at 10 μg/mL; 2 hours at room temperature) blocks human TSLP binding to its receptor complex on transfected HEK293T cells with an IC50 of 29.13 ng/mL (0.2 nM)[1].
TAVO101 binds human TSLP with high affinity, having an average KD of 0.85 nM as measured by BLI[1].
TAVO101 (Serial 3-fold dilutions starting at 10 μg/mL; 24 hours) potently neutralizes TSLP-driven STAT5 reporter activation in transfected HEK293T cells with an IC50 of 5.27 ng/mL (35.13 pM)[1].
TAVO101 (Serial 3-fold dilutions starting at 1 μg/mL; 2 days) neutralizes TSLP-driven proliferation of transfected BaF3 cells with an IC50 of 6.6 ng/mL (44 pM)[1].
TAVO101 (1 μg/mL; 2 days) inhibits TSLP-driven CCL17 release from primary human CD1c+ dendritic cells isolated from healthy donor PBMC[1].
TAVO101 (3.03-33 μg/mL; 6 days) concentration-dependently inhibits TSLP-driven proliferation of activated primary human CD4+ T cells isolated from healthy donor PBMC[1].
TAVO101 (0.0001-100 nM; 2 h) potently binds to recombinant human TSLP (EC50 ~0.13 nM) in ELISA binding assays, and does not bind to recombinant human IL-4Rα or IL-4Rα/IL-13Rα1 receptor complex[3].
TAVO101 (0.001-100 nM; 2 h) inhibits human TSLP binding to its cell surface receptor complex on transfected Expi293F cells with an IC50 of ~0.82 nM[3].
TAVO101 (0.001-100 nM; 24 h) neutralizes human TSLP-driven STAT5 reporter gene expression in transfected HEK293T cells with an IC50 of ~0.08 nM[3].
TAVO101 (3 µg/mL; 6 days) significantly reduces Der p-stimulated IL-5 and CCL26 release from co-cultures of human PBMCs, MRC-5 cells, and A549 cells, with a less dramatic reduction in IL-5 levels than the bispecific antibody TAVO101 × IL4R-dupi[3].
TAVO101 (1-10000 ng/mL; 2 days) partially inhibits TSLP/IL-4-stimulated CCL17 release from activated human CD14+ monocytes by blocking the TSLP-mediated boost in production, reducing levels to the IL-4-alone baseline[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BaF3 mouse pro-B cells co-transfected with human IL-7Rα and TSLPR
-
Concentration:Serial 3-fold dilutions starting at 1 μg/mL; 0.5 ng/mL human TSLP
-
Incubation Time:2 days (with antibody and TSLP); 16-20 hours (with resazurin)
-
Result:Concentration-dependently neutralized TSLP-driven cell proliferation, with an IC50 of 6.6 ng/mL (44 pM).
TAVO101 (10 mg/kg; i.p.; single dose on Day 1, followed by 3 mg/kg; every other day for four additional doses) reduces clinical, cytokine, and histopathological markers of psoriasis in hTSLP/hTSLPR humanized mice, with superior efficacy in reducing skin scaling compared to Tezepelumab at the same dosing regimen[1].
TAVO101 (3-10 mg/kg; i.p.; twice weekly; 20 days) produces a 33%-35% improvement in skin lesion scores and significant reductions in ear thickness, serum IgE, and ear tissue IL-4 levels in oxazolone-induced atopic dermatitis in hTSLP/hTSLPR double knock-in mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:hTSLP/hTSLPR double knock-in mice (C57BL/6 background)[1]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg
-
Administration:i.p.; Day -1 and Day 6
-
Result:Dose-dependently reduced serum total IgE levels relative to the isotype control group.
Reduced serum IgE to levels similar to tezepelumab at 3 mg/kg at 10 mg/kg.
Significantly mitigated TSLP/OVA-induced increases in lung CCL17 and IL-13 levels.
Dose-dependently reduced the number and proportion of CD45+ leukocytes and eosinophils in BALF.
Significantly reduced inflammatory cell and eosinophil infiltration around blood vessels and bronchioles, as well as mucus overproduction and goblet cell metaplasia in bronchioles.
-
Animal Model:hTSLP/hTSLPR double knock-in mice (C57BL/6 background)[1]
-
Dosage:10 mg/kg (Day 1); 3 mg/kg (every other day for four additional doses)
-
Administration:i.p.; single dose on Day 1; every other day for four additional doses
-
Result:Reduced skin thickness, redness, scaling, and total PASI scores relative to the untreated imiquimod-exposed group.
Produced statistically significant improvement in skin scaling score on Day 10 compared to tezepelumab.
Significantly mitigated imiquimod-induced increases in skin human TSLP, IL-6, TNF-α, and IL-1β levels.
Reduced imiquimod-induced increases in skin epithelium thickness and histopathological lesion scores.
-
Animal Model:hTSLP/hTSLPR double knock-in mice (C57BL/6 background; oxazolone-induced atopic dermatitis model)[2]
-
Dosage:3 mg/kg; 10 mg/kg
-
Administration:i.p.; twice weekly; 20 days
-
Result:Significantly reduced average ear thickness compared to PBS-treated controls over the 26-day study period, with enhanced effectiveness in the rebound phase of inflammation.
Achieved total histopathology skin lesion scores of 3.00 and 2.92, representing a 33%-35% improvement relative to the PBS control (score 4.50).
Reduced eosinophil infiltration by approximately 44%.
Significantly lowered serum IgE concentrations and IL-4 levels in ear tissue homogenates compared to PBS controls.
Q969D9-1
TSLP
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Shi L, et al. A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases. Front Immunol. 2024;15:1442588. Published 2024 Dec 11. [Content Brief]
[2]. Han C, et al. Phase 1 Safety and Pharmacokinetics Study of TAVO101, an Anti-Human Thymic Stromal Lymphopoietin Antibody for the Treatment of Allergic Inflammatory Conditions. J Clin Pharmacol. Published online August 14, 2024. [Content Brief]
[3]. Yu M, et al. A Bispecific Antibody Blocking Both TSLP and IL-4Rα for the Treatment of Allergic Inflammatory Diseases. Cells. 2025 Nov 7;14(22):1747. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TAVO101 Related Classifications
HY-P992474 Related Classifications
Powered by Bioz